Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Gadoteridol

Gadoteridol: 2 brands, 1 generic; first approved Nov 16, 1992; generic available.

Generic available
Generic status & protection

Generic available: 1 ANDA application approved.

Brands (NDA)
2
Generics (ANDA)
1
Listed patents
0
Presentations
3

Brand (NDA) products

Originator applications
  • NDA 0214892003
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    279.3MG/MLINJECTABLEINJECTIONRx—
  • NDA 0201311992
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    279.3MG/MLINJECTABLEINJECTIONRxAP

Generic (ANDA) products (1)

Abbreviated applications
  • GADOTERIDOL
    ANDA 2187492025
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    279.3MG/MLINJECTABLEINJECTIONRxAP

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
34 yr 5 mo ago
Most recent approval
1 yr 8 mo ago

Approvals span 1992–2025 across 3 FDA applications.

Brand (NDA) 267%
Generic (ANDA) 133%

Gadoteridol: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.